Ron Blankstein retweeted
In med school, I founded the PowerPoint Academy and taught students/professors/professionals to give effective academic presentations.
So yes, I feel conflicted about the boom of AI-generated slides at conferences.
8 tips so your AI slides don’t look like everyone else’s 🧵
Ron Blankstein retweeted
ZEUS trial: Ziltivekimab 15 mg SC once-monthly yielded comparable 3-point MACE incidence rate vs. placebo (6.7 vs. 6.8 per 100 person-years) over a median on-treatment period of 33 months in high-risk patients with ASCVD and CKD, showing no significant clinical benefit.
Download slides here: clinicaltrialresults.org/wp-…
Ron Blankstein retweeted
Atherosclerosis across the Adult Lifespan — A Call to Act from REACT | New England Journal of Medicine nejm.org/doi/10.1056/NEJMe26… - Congratulations to my long-time & most favorite collaborator Professor @WendyPost9 & the Dak Professor of 🫀@dramitkhera @CiccaroneCenter @hopkinsheart
Ron Blankstein retweeted
Important announcement!
scct.org/page/EICcall2026?_z…
Ron Blankstein retweeted
Cover Story | Inflammation as a Treatable Target: The Rise of Cardio-Immunology - American College of Cardiology acc.org/Latest-in-Cardiology…
Inspiring story @UVACVRC
Presented at #TCT2026:
In a randomized trial, CCTA-guided PCI with structured preprocedural planning and intraprocedural guidance was noninferior to intravascular ultrasound–guided PCI with respect to target-vessel failure at 12 months. Full P4 trial results: nej.md/48jfVly
@crfheart

ALT A graph from the Original Article "Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI." The trial name, P4, is in parentheses after the title. The graph shows the cumulative incidence of target-vessel failure (primary end point), defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization, at 12 months. The trial results are being presented at the Transcatheter Cardiovascular Therapeutics 2026 Conference. The logo of the New England Journal of Medicine is at the bottom.
Ron Blankstein retweeted
P4 is out: CT-guided PCI was noninferior to IVUS-guided PCI for 12-mo TVF (4.1% vs 4.6%; n=1,105, 23 centers). Procedures were 17 min shorter with less contrast and radiation, and safety was similar. CT moves from gatekeeper to procedural tool. #TCT2026 @ColletCarlos
Ron Blankstein retweeted
What is HALT? How is it different from valve thrombosis or pannus?
Confused by the terminology? Join us at #TCT2026 session in complex case theatre 2 as we decode the differences, explore key multimodality imaging insights, and discuss treatment strategies through exciting cases
From imaging to management—let’s clear the confusion! 🫀
Ron Blankstein retweeted
The present of advanced submillimetric imaging is PHOTON COUNTING CT.
This is today not tomorrow, in 5 or 10 years.
This is a new imaging modality.
It's a new approach, a new semeiology, a new opportunity for better outcomes and more personalized care.
And tomorrow PCCT will also provide molecular imaging.
Ron Blankstein retweeted
.@WilliamZoghbi What an honor to host you @Lahey_Clinic for Cardiology and Medicine Grand Rounds! You are an inspiration! Thank you for so many educational and life lessons! @HMethodistCV
Ron Blankstein retweeted
In our new @masala_study analysis @JACCJournals, Lp(a) levels vary among disaggregated South Asian groups, but the association between Lp(a) levels and outcomes does not.
@UCSDCardiology @UCSDCardFellows
sciencedirect.com/science/ar…
Ron Blankstein retweeted
A prevention conundrum:
- LDL-C lowering is prioritized after an ASCVD event because near-term absolute risk is high.
- Yet relative benefit is greater before a first event and at younger ages.
sciencedirect.com/science/ar… (Burger PM et al Atherosclerosis 2024)
We need to keep moving toward improving high lifetime-risk identification before the disease declares itself.
Ron Blankstein retweeted
How can the new FFR-CT consensus recommendations translate into everyday clinical practice? Join SCCT/ @SCAI experts for practical guidance on patient selection, image acquisition and standardized reporting.
Register: ow.ly/Hz7F50ZYcHX
Ron Blankstein retweeted
There's still time to join us for the SCCT Cardiovascular Disease Prevention Symposium kicking off today at 10:20am ET.
Learn more: scct.org/page/PreventionSymp
SCCT thanks @ElucidBio and @Heartflow for their support of this event.
Ron Blankstein retweeted
Replying to @khurramn1 @FiRSTSCCT @RonBlankstein @rblument1 @MichaelJBlaha @HMethodistCV @DrMichaelShapir @ASPCardio @AJPCardio
That slide is brilliant- Dikec standing in for CAC made me laugh out loud. Kudos to you and Ron. CTA in asymptomatic individuals is exactly the question we keep facing in clinic. Registered.
Ron Blankstein retweeted
Join us tomorrow online for a fantastic
@FiRSTSCCT annual prevention symposium led by @RonBlankstein
register here
scct.org/page/PreventionSymp
I am talking about role of CTA in asymptomatic individuals
This slide summarizes the talk👇
Ron Blankstein retweeted
Why Weight Lifting Is Good for Your Heart nytimes.com/2026/10/09/well/… @MeaganWasfy
Ron Blankstein retweeted
What does lifestyle-first prevention look like in 2027? Join the CVD Symposium for talks on integrating AI, wearables & emerging technologies into patient care, w/ practical guidance on exercise, sleep & nutrition for patients w/ coronary heart disease.
ow.ly/UcK650ZV3Ec
Ron Blankstein retweeted
Replying to @loridanielsmd
@loridanielsmd kicking off the #proCardioForum with a great overview of the new gen six troponin assay. @procardioforum @ambarish4786 @mvaduganathan @RonBlankstein @lamcardio @yadersandoval
Ron Blankstein retweeted
Replying to @CarlosVergaraMD @DineshKalra @nationallipid @ASPCardio @AJPCardio @khurramn1 @DrMichaelShapir @MichaelJBlaha
Part 3: where are we with AI plaque analysis, how does it correlate with risk, and take home points. @nationallipid
@AJPCardio @ASPCardio @khurramn1 @DineshKalra @DrMichaelShapir @RonBlankstein @PrajReddyMD @EugeniaGianos




































